JP7121396B2 - バリアントフラビウイルスエンベロープ配列およびその使用 - Google Patents

バリアントフラビウイルスエンベロープ配列およびその使用 Download PDF

Info

Publication number
JP7121396B2
JP7121396B2 JP2018561062A JP2018561062A JP7121396B2 JP 7121396 B2 JP7121396 B2 JP 7121396B2 JP 2018561062 A JP2018561062 A JP 2018561062A JP 2018561062 A JP2018561062 A JP 2018561062A JP 7121396 B2 JP7121396 B2 JP 7121396B2
Authority
JP
Japan
Prior art keywords
protein
flavivirus
fusion loop
modified
dengue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018561062A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520058A5 (enExample
JP2019520058A (ja
Inventor
ラング，ペーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Excivion Ltd
Original Assignee
Excivion Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Excivion Ltd filed Critical Excivion Ltd
Publication of JP2019520058A publication Critical patent/JP2019520058A/ja
Publication of JP2019520058A5 publication Critical patent/JP2019520058A5/ja
Application granted granted Critical
Publication of JP7121396B2 publication Critical patent/JP7121396B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
JP2018561062A 2016-05-20 2017-05-22 バリアントフラビウイルスエンベロープ配列およびその使用 Expired - Fee Related JP7121396B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1608896.5A GB2550418A (en) 2016-05-20 2016-05-20 An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
GB1608896.5 2016-05-20
PCT/US2017/033882 WO2017201543A1 (en) 2016-05-20 2017-05-22 Variant flavivirus envelope sequences and uses thereof

Publications (3)

Publication Number Publication Date
JP2019520058A JP2019520058A (ja) 2019-07-18
JP2019520058A5 JP2019520058A5 (enExample) 2020-07-02
JP7121396B2 true JP7121396B2 (ja) 2022-08-18

Family

ID=56369688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018561062A Expired - Fee Related JP7121396B2 (ja) 2016-05-20 2017-05-22 バリアントフラビウイルスエンベロープ配列およびその使用

Country Status (18)

Country Link
US (2) US11028133B2 (enExample)
EP (2) EP3458471B1 (enExample)
JP (1) JP7121396B2 (enExample)
KR (1) KR20190008896A (enExample)
CN (1) CN109415414A (enExample)
AU (1) AU2017268479B2 (enExample)
BR (1) BR112018073681A2 (enExample)
CA (1) CA3025076A1 (enExample)
DK (1) DK3458471T3 (enExample)
GB (2) GB2550418A (enExample)
HU (1) HUE049543T2 (enExample)
IL (1) IL263054A (enExample)
MX (1) MX2018014198A (enExample)
PE (1) PE20190130A1 (enExample)
PH (1) PH12018502441A1 (enExample)
RU (1) RU2018142835A (enExample)
SG (1) SG11201810157QA (enExample)
WO (2) WO2017201543A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies
US10849943B2 (en) * 2016-06-23 2020-12-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vaccine compositions comprising an attenuated mutant Zika virus
EP3621645A4 (en) 2017-05-10 2021-01-27 University of Massachusetts BIVALENT VACCINES AGAINST DENGUE / HEPATITIS B
TWI658848B (zh) * 2018-02-13 2019-05-11 National Tsing Hua University 茲卡病毒疫苗組合物及其應用
CN109627294B (zh) * 2018-12-29 2020-10-09 四川大学 一种正确折叠的重组狂犬病毒g蛋白胞外段及其潜在应用
WO2020198865A1 (en) * 2019-04-03 2020-10-08 The University Of British Columbia Oligopeptides for quantitative viral proteomic analysis methods and uses
JP7725465B2 (ja) * 2019-11-07 2025-08-19 中国科学院微生物研究所 ジカ・デングワクチン及びその使用
CN117157524A (zh) * 2020-10-07 2023-12-01 赛诺菲巴斯德有限公司 改良的诊断测试
CA3198059A1 (en) * 2020-10-07 2022-04-14 Sanofi Pasteur Improved diagnostic tests
GB202019843D0 (en) 2020-12-16 2021-01-27 Coronex Ltd Lateral flow tests
EP4602057A1 (en) * 2022-10-11 2025-08-20 University of Maryland, Baltimore Engineered flavivirus envelope glycoprotein immunogenic compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
WO2007015783A2 (en) 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
US7943148B1 (en) 2007-04-04 2011-05-17 The United States Of America As Represented By The Secretary Of The Army Amino acid sites in Flavivirus E proteins useful for development of diagnostics and vaccines
EP2834265A4 (en) * 2012-04-02 2015-10-14 Univ North Carolina METHOD AND COMPOSITIONS FOR DENGUE VIRUS EPITOPES
GB201413086D0 (en) * 2014-07-23 2014-09-03 Imp Innovations Ltd And Inst Pasteur Methods
GB2550418A (en) * 2016-05-20 2017-11-22 Laing Peter An improved vaccine against flaviviruses avoiding elicitation or stimulation of infection-enhancing antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF VIROLOGY, 2011, Vol.85, pp.11800-11808
Journal of Virology, 2013, Vol.87, pp.52-66
ウイルス, 2011, 第61巻, 第2号，pp.221-238

Also Published As

Publication number Publication date
DK3458471T3 (da) 2020-07-06
GB201719423D0 (en) 2018-01-03
AU2017268479A1 (en) 2018-12-06
BR112018073681A2 (pt) 2019-02-26
HUE049543T2 (hu) 2020-09-28
EP3458471A1 (en) 2019-03-27
US11401307B2 (en) 2022-08-02
GB2550418A (en) 2017-11-22
WO2018215495A1 (en) 2018-11-29
MX2018014198A (es) 2019-08-21
CA3025076A1 (en) 2017-11-23
RU2018142835A (ru) 2020-06-22
PE20190130A1 (es) 2019-01-17
US20200215180A1 (en) 2020-07-09
GB201608896D0 (en) 2016-07-06
IL263054A (en) 2019-01-31
AU2017268479B2 (en) 2021-04-01
US11028133B2 (en) 2021-06-08
CN109415414A (zh) 2019-03-01
KR20190008896A (ko) 2019-01-25
EP3630796A1 (en) 2020-04-08
US20190300580A1 (en) 2019-10-03
PH12018502441A1 (en) 2019-05-15
WO2017201543A1 (en) 2017-11-23
SG11201810157QA (en) 2018-12-28
JP2019520058A (ja) 2019-07-18
EP3458471B1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
EP3458471B1 (en) Variant flavivirus envelope sequences and uses thereof
Sánchez et al. Characterization of neutralizing antibodies to West Nile virus
JP4500049B2 (ja) フラビウイルスｎｓ１サブユニットワクチン
Costa et al. DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice
Block et al. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice
KR20010022452A (ko) 플라비바이러스 감염에 대한 재조합 다이머형 엔벨롭 백신
EP3468591A1 (en) Neutralising antibody against dengue for use in a method of prevention and/or treatment of zika infection
KR20130138789A (ko) 재조합 서브유닛 뎅기 바이러스 백신
AU2010257162B2 (en) Recombinant subunit West Nile virus vaccine for protections of human subjects
CN102906266A (zh) 登革病毒通用序列及其使用方法
EP3269728B1 (en) Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
AU4329699A (en) Nucleic acid vaccines for prevention of flavivirus infection
WO2018237313A1 (en) VIRAL PSEUDO PARTICLES COMPRISING A ZIKA ANTIGEN
AU2015276929B2 (en) Chimeric West Nile/Dengue viruses and methods of use
Wang et al. Rational design of flavivirus E protein vaccine optimizes immunogenicity and mitigates antibody dependent enhancement risk
EP2086526B1 (en) Induction of an immune response against Dengue virus using prime-boost approach
JP6985458B2 (ja) ワクチン
WO2015019253A2 (en) Anti-dengue virus genetic vaccine based on the envelope protein ectodomains
US20220017605A1 (en) Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof
HK1261267A1 (en) Variant flavivirus envelope sequences and uses thereof
CN112334576A (zh) 黄病毒的成熟病毒样颗粒
HK1163744A (en) Flavivirus ns1 subunit vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220729

R150 Certificate of patent or registration of utility model

Ref document number: 7121396

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees